EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSCHOG00000003996
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSCHOG00000011766
Gene Symbol: PDGFRA
1 Cross references
204 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSCHOG00000009990
Gene Symbol: PLK1
1 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSCHOG00000007040
Gene Symbol: PLK4
1 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSCHOG00000003539
Gene Symbol: PARP1
1 Cross references
207 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSCHOG00000007172
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSCHOG00000010966
Gene Symbol: KCNMA1
1 Cross references
297 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSCHOG00000000539
Gene Symbol: KCNJ11
1 Cross references
190 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSCHOG00000013971
Gene Symbol: KCNJ2
1 Cross references
273 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSCHOG00000007026
Gene Symbol: KCNJ5
1 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSCHOG00000003083
Gene Symbol: KCNK2
1 Cross references
284 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSCHOG00000010336
Gene Symbol: KCNQ3
1 Cross references
193 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).